Polypill, Drug for Longevity
The concept of this product has been coined by the British Medical Journal from 2003 as a means to reduce cardiovascular risks by up to 88%.
The effects
Drugs that make up the Polyprill are chosen to:
- Reduce bad cholesterol.
- Reduce blood pressure.
It must be taken at age 55.
It is not totally without side effects but they affect only 10% of the population.
Composition of Polypill
Composition of Polypill against cardiovascular disease:
- A statin against cholesterol, such as simvastatin.
- A beta-blocker such as atenolol.
- An enzyme inhibitor as enalapril.
- Folic acid 0.8 mg.
- Aspirin 75 mg/d.
- A diuretic such as bendroflumethiazide.
Composition against diabetes:
- A statin.
- An ACE inhibitor .
- Aspirin.
- Metformin, a medication against diabetes.
It goes without saying that these compositions of medications should
not be done ourselves but must be under medical control, the best being to
wait for the selling of a drug in a pill.
Alternatively you can also turn to a pure food alternative performed without any risk …
Aspirin
The inclusion of aspirin in the polypill ingredients is hotly contested by the doctors. Taken regularly by a person who is doing well, she would have more disadvantages than health benefits. It causes internal bleeding that could grow and sometimes lead to death.
We should therefore use of aspirin against cardiac risk if it is sufficiently high to compensate the disadvantages and other risks.
Drug or food
The same newspaper that launched the concept of Polypill, also
offers a natural alternative, the Polymeal. This is done by adding in
its daily ration wine, fish, garlic, almonds, fruit and vegetables
in a sufficient proportion. The advantage is that it has no side
effects, unlike drugs.
External Links
Polymeal. A natural alternative to Polypill statistically reduces
the risk of cardiovascular disease by 75%, without side effects.
Reference
Wald and Law. A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal, on June 29, 2003.
Peter Weissberg. Study on aspirin made public to the European Society of Cardiology Congress in Barcelona.